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Introduction
Glaucoma affects nearly 70 million people 
worldwide, of which nearly half are in Asia.1 
Although more people are affected by 
primary open-angle glaucoma (POAG) than 
by primary angle-closure glaucoma (PACG), 
the latter is more common in Asians and 
carries a higher burden of morbidity. An 
estimated 13.6 million people will suffer 
from PACG in Asia by 2010, of which nearly 
3.5 million will be bilaterally blind.2 Unlike 
cataract, visual loss from glaucoma is 
irreversible. The methods for management 
of POAG are similar to those described in 
the other sections of this issue, therefore we 
will concentrate on PACG in this article. 
Traditional definitions of PACG have 
emphasised the symptomatic aspect of the 
disease. However, only 25 per cent of PACG is 
symptomatic, therefore more modern defini-
tions rely on objective evidence of damage to 
the trabecular meshwork and optic nerve.3 A 
diagnosis of glaucoma means that there is 
damage to the optic nerve as shown by 
changes in the optic disc and a characteristic 
visual field defect. One important distinction 
is that acute angle closure, where there is a 
sudden rise in intraocular pressure (IOP) 
causing pain and blurred vision, is not 
considered as glaucoma. 
As management pathways for PACG are 
different to that of POAG, accurate detection 
as well as treatment are important when 
dealing with glaucoma in Asia.
Population	burden	of	
glaucoma
PACG is largely asymptomatic. Therefore, 
there are a large number of patients in the 
community who have undiagnosed disease. 
A glaucoma survey in Mongolia showed that 
91 per cent of patients were not aware that 
they had glaucoma,4 and in a similar survey 
in Singapore this figure was 21 per cent. 
This suggests that economic conditions and 
health service provision are a consideration 
in the population burden of the disease.
Age and gender are major risk factors for 
PACG. Angle closure is rare before the age 
of 40 and more common in females. The 
main anatomical risk factors are shorter 
axial length and a shallow anterior chamber 
depth (ACD). Asian people who present with 
an acute episode of angle closure have 
shorter axial lengths compared to those with 
chronic angle closure, and both these 
groups have shorter axial lengths than 
people without angle closure. Although 
anterior chamber depth is correlated with 
angle closure in different populations of 
Asian descent, there is a suggestion that 
this association differs between different 
populations.5
There is little information about the 
natural history of the disease. Current under-
standing indicates that people at risk of 
disease develop an anatomically narrow 
angle (or primary angle-closure suspect, 
PACS) with no other abnormality. Signs of 
prolonged appositional closure can appear 
afterwards, where there is raised IOP or 
peripheral anterior synechiae (PAS); this is 
termed primary angle closure (PAC). The final 
stage is angle closure combined with a 
glaucomatous optic neuropathy (GON) where 
there is structural damage to the neuroretinal 
rim of the optic disc and a reproducible visual 
field defect. This is classified as PACG. 
Recent data from south India describes the 
natural history of normal subjects and people 
with narrow drainage angles who were 
enrolled from a population survey. Among the 
people with narrow drainage angles (PACS), 
22 per cent (95 per cent CI: 9.8, 34.2) had 
developed synechial (64 per cent) or apposi-
tional angle closure (36 per cent) over a 
period of five years.6 Twenty-eight people with 
established angle closure at baseline were 
also examined, and 8 out of 28 (28 per cent, 
95 per cent CI: 12, 45) had progressed to 
PACG over five years.7 In this group, one of 
nine who had laser peripheral iridotomy (LPI) 
at baseline had progressed compared to 7 of 
19 who refused LPI. Although more information 
on the natural history and progression of 
angle closure is needed, in the context of the 
existing knowledge there is a strong 
protective effect from peripheral iridectomy. 
Primary angle-closure glaucoma is a 
good candidate for screening; the population 
undergoes a simple test to detect those at 
risk or with early disease, who are then 
subsequently referred for diagnosis and 
treatment. However, the paucity of data on 
the natural history of the disease will hamper 
the understanding of the potential benefits 
of prophylactic treatment, and we are 
awaiting results of a randomised controlled 
trial assessing this strategy. 
Treatment
Medical	therapy
There is clear evidence that reduction of IOP 
with medical therapy is effective in preventing 
the onset of POAG8 and averting the progression 
of early POAG.9 However, the cost of maintaining 
therapeutic goals to prevent one case is too high 
for resource-poor countries. In addition, these 
trials were performed on western populations 
and the generalisability of the results is 
limited, especially when considering calcula-
tions such as numbers needed to treat. In 
patients with angle closure and a patent 
peripheral iridectomy, medical treatment 
with latanoprost is effective at reducing IOP, 
even in the presence of synechiae.10
Peripheral	iridotomy
Laser or surgical peripheral iridotomy (PI) is 
the mainstay of treatment for angle closure. 
There is strong evidence to show the 
protective effect of PI in the fellow eye in a 
patient presenting with an acute attack, and 
this is standard practice worldwide. In units 
where laser treatment is not available, a 
surgical PI is as effective as laser PI. The 
emphasis is that patients with an acute 
attack should not leave the treatment unit 
without a PI in both eyes. The presence of a 
PI, together with medical and other laser 
treatments, will often be successful even 
when early glaucomatous damage has 
occurred to disc and field. In Asian eyes, PI 
alone may be insufficient for long-term IOP 
control following acute angle closure; in one 
study from Singapore 58 per cent of such 
eyes required additional methods of 
management, including trabeculectomy.11 
In patients who have not suffered 
symptoms from angle closure, there is no 
published evidence on the efficacy of prophy-
lactic PI for PACS. However, a longitudinal 
study from Mongolia showed that when PIs 
were performed on eyes with PAC or PACG, 
these eyes were more likely to require further 
treatment than eyes with the earlier stage of 
PACS. As a PI can protect a fellow eye from 
an acute attack, current practice is based on 
the assumption that it will protect a predis-
posed individual to a first attack. Therefore, 
current expert consensus suggests that all 
eyes with angle closure require a PI to protect 
them from an acute attack and to eliminate 
pupil block. This is especially the case in 
developing countries, where treatment 
centres can be very far away for the patient. 
Laser	iridoplasty	
Iridoplasty refers to a method where the 
position of the peripheral iris is altered by 
applying contraction burns. This pulls the 
peripheral iris away from the angle structures 
and can reverse appositional closure. Current 
expert opinion suggests that if IOP is not 
promptly controlled by medical means in an 
acute attack, the patient should be 
considered for laser iridoplasty. In cases of 
asymptomatic angle closure due to plateau 
iris (in which a PI has been performed), irido-
plasty can increase the angle width. Limited 
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capacity restricts the use of this therapy to the popula-
tions of developing countries. 
Surgery
Surgery can be offered as a single intervention in 
cases where glaucoma has been diagnosed. It 
carries more risks than medical and laser treatment; 
but these are offset by lower long-term costs and the 
fact that there are no compliance issues, especially 
important in developing countries. The details of 
trabeculectomy and management of complications is 
covered by other articles in this issue.
Lens extraction is an attractive alternative for the 
treatment of angle closure. This will eliminate pupil 
block, lens-induced angle closure, and can also have 
beneficial effects on other mechanisms of angle 
closure. There is limited information on the long-term 
success of this form of management. However, lens 
extraction alone is most effective in the early stages 
of the disease where there is less than 180 degrees 
of synechiae and minimal damage to the trabecular 
meshwork. In the presence of glaucoma and a 
clinically significant cataract, a combined cataract/ 
glaucoma procedure would be a logical approach for 
PAC(G). There is presently insufficient evidence to 
suggest that performing the two surgical procedures 
separately is better than a single combined 
operation.12 In resource-poor settings, where follow-
up may be problematic and expensive for the patient, 
a single procedure may be more appropriate.
Conclusion
Primary angle-closure glaucoma is an important 
cause of blindness in Asia. Ophthalmic practitioners 
in Asian countries should focus on accurate 
detection and prevention of acute attacks and 
blindness from PACG with appropriate laser and 
surgical treatment.
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Laser	iridotomy
Indications
• in both eyes of patients who suffer 
an acute episode of angle closure
• patients with asymptomatic narrow 
angles, established primary angle 
closure, and those with primary 
angle closure and early glauco-
matous optic neuropathy. 
1 Explain the reasons for carrying out 
the procedure, what it will feel like, 
and what to expect afterwards.
2 Instil pilocarpine 2% for blue eyes 
and 4% for brown-eyed patients, 
and apraclonidine 0.5% (unless 
contra-indicated) half an hour 
before, and again five minutes 
before the procedure.
3 Ensure the laser is set to zero 
defocus.
4 Anaesthetise the cornea, and 
insert a Wise or Abrahams lens.
5 If possible, identify an iris crypt 
(indicating a thin area of iris) in the 
peripheral iris at, or very close to, 
12 o’clock. Take very careful aim 
on the most peripheral area of iris 
that can be seen adjacent to the 
limbal zone. Accurate focussing 
increases the effectiveness of the 
laser energy considerably.
						Argon
6 Argon laser pre-treatment is 
very useful in achieving a laser 
iridotomy in thick, deeply 
pigmented irises.
7 Set the laser to 50 µm spot, 
120 mW, 0.05 s, and apply 
approximately 30 laser shots to the 
iris in an overlapping rosette 
pattern to achieve a ‘beaten 
copper’ appearance on the surface 
of the iris. This helps to avoid large, 
adherent bubbles when performing 
the second phase of laser.
8 Set the laser to 50 µm spot, 
700 mW, 0.1 s and apply approxi-
mately 5 to 10 laser shots to the 
iris in the same area to form a 
crater in the stroma. Complete the 
iridotomy with a few, low-power 
shots of YAG laser
					YAG
9 Multiple lower energy shots (0.6 to 
1.2 mJ) are most effective, and 
prevent the dispersion of pigment 
that may cause pressure spikes. 
The use of argon pre-treatment in 
dark brown irises is important.
Laser	iridoplasty
Indications
• for short-term control of 
intraocular pressure in an acute, 
symptomatic episode of angle 
closure (either primary or 
phacomorphic), prior to definitive 
management (laser iridotomy or 
cataract surgery)
• for management of extensive 
(more than 180 degrees) residual 
appositional angle closure after 
laser iridotomy in eyes without 
peripheral anterior synechiae.
Steps 1, 2 and 4 as above for 
iridotomy.
5 Set a continuous wave laser 
(argon, frequency doubled YAG or 
diode) to 500 µm spot size and 0.5 
to 1.0 seconds.
6 Apply laser around 4 or 5 shots of 
laser per quadrant to the extreme 
periphery of the iris, taking care not 
to apply laser to areas of irido-
corneal contact. 
7 Start with a power of around 
100 mW increasing until a brisk 
contraction of the iris, but without 
pops or cracks (if so, turn the 
power down).
Aftercare
Intraocular pressure should be 
measured at least one hour after 
treatment. If IOP is high, the protocol 
used at Moorfields Eye Hospital is:
If IOP above 30 mm Hg
• 250 mg acetazolamide orally stat.
• 125 mg acetazolamide tds for two 
days.
If IOP above 40 mm Hg
• acetazolamide and topical 
treatment as appropriate.
A response to therapy must be 
demonstrated before discharge.
All patients then receive 
prednisolone 1% (Pred Forte) hourly 
for 24 hours (taking a break through 
the night), and then four times a day 
until seen in clinic one week later. All 
regular medication for glaucoma is 
continued in both eyes.
Clinic
All patients are seen one week later in 
clinic and re-gonioscoped. Stop 
steroids, unless there is evidence of 
continued inflammation. If the IOP is 
raised and there is anterior segment 
inflammation, swap to a topical NSAID.
Laser	treatment	for	angle	closure
Laser treatment is the cornerstone of management of angle closure, 
and is generally very effective. However, lasers are powerful surgical 
tools, which, if used incorrectly, can do considerable harm. The following 
is intended as a guide for experienced users.
